B+
Bull case
20%
Probability
Target price
$25.00
+55.3% vs current
SNSE
Sensei BiotherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.00
-56.5% vs current
B-
Bear case
35%
Probability
Target price
$1.50
-90.7% vs current
AI sentiment snapshot
Latest data as of 2026-05-20
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+1.9
Score
AI commentary
News flow is constructive because Sensei has moved PIKTOR into a fresh breast-cancer study and still has a funded endometrial readout on the calendar, but the stock remains a thin-coverage, event-driven biotech with material structure risk. The available peer set is mostly broad micro-cap clinical-biotech context rather than direct PIKTOR comparables, and there is no reliable analyst-revision signal or usable social context in the packet. This should remain a tentative monitoring setup rather than a standard-conviction bullish thesis.
RankAlpha Sentiment Codex - 2026-05-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystRecently initiated PIKTOR breast-cancer trial moves into executionHigh impact
The 10-Q says Sensei expects R&D spending to rise as it advances PIKTOR through the ongoing Phase 2 endometrial-cancer trial and the recently initiated Phase 1b/2 HR+/HER2- advanced breast-cancer trial, making trial execution the nearest operating proof point for the post-Faeth thesis [#10-Q-2026-05-15].
2026-08-20eventSeries B stockholder-approval and cash-settlement overhangHigh impact
The 10-Q says the Series B preferred stock can become eligible for cash settlement if stockholder approval is not obtained within six months of issuance, and the auditor's going-concern paragraph remains tied to that contingent obligation rather than cash burn alone [#10-Q-2026-05-15].
2026-12-31catalystPIKTOR topline endometrial readout remains the main rerating eventHigh impact
Sensei said the February financing was intended to fund topline data from the ongoing Phase 2 endometrial-cancer trial and the start of the Phase 1b breast program by year-end 2026, keeping the principal rerating event in the back half of the year [#PR-2026-02-18].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-20 • Updated nightlySource: Internal modelMethodology